BIOMARKER:

EGFR wild-type

A1 | Sensitive

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Non-Squamous Non-Small Cell Cancer

Lung Adenocarcinoma

Lung Non-Small Cell Squamous Cancer

Tongue Carcinoma

docetaxel + BPI 2358

EGFR wild-type|Non Small Cell Lung Cancer|docetaxel + BPI 2358

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|docetaxel + BPI 2358

cemiplimab-rwlc

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|cemiplimab-rwlc

EGFR wild-type|Lung Non-Small Cell Squamous Cancer|cemiplimab-rwlc

atezolizumab

EGFR wild-type|Non Small Cell Lung Cancer|atezolizumab

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|atezolizumab

durvalumab + tremelimumab

EGFR wild-type|Non Small Cell Lung Cancer|durvalumab + tremelimumab

nivolumab + bevacizumab

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|nivolumab + bevacizumab

nivolumab + ipilimumab

EGFR wild-type|Non Small Cell Lung Cancer|nivolumab + ipilimumab

PSB205

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|PSB205

EGFR wild-type|Lung Non-Small Cell Squamous Cancer|PSB205

pemetrexed

EGFR wild-type|Non Small Cell Lung Cancer|pemetrexed

EGFR wild-type|Lung Adenocarcinoma|pemetrexed

tislelizumab

EGFR wild-type|Non Small Cell Lung Cancer|tislelizumab

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|tislelizumab

rivoceranib

EGFR wild-type|Non Small Cell Lung Cancer|rivoceranib

EGFR wild-type|Lung Adenocarcinoma|rivoceranib

anlotinib

EGFR wild-type|Non Small Cell Lung Cancer|anlotinib

durvalumab

EGFR wild-type|Non Small Cell Lung Cancer|durvalumab

toripalimab-tpzi

EGFR wild-type|Non Small Cell Lung Cancer|toripalimab-tpzi

erlotinib

EGFR wild-type|Non Small Cell Lung Cancer|erlotinib

pembrolizumab

EGFR wild-type|Non Small Cell Lung Cancer|pembrolizumab

nivolumab

EGFR wild-type|Non Small Cell Lung Cancer|nivolumab

sintilimab

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|sintilimab

MK-2870

EGFR wild-type|Non Small Cell Lung Cancer|MK-2870

anlotinib + sintilimab

EGFR wild-type|Non Small Cell Lung Cancer|anlotinib + sintilimab

cabozantinib tablet

EGFR wild-type|Non Small Cell Lung Cancer|cabozantinib tablet

erlotinib + cabozantinib tablet

EGFR wild-type|Non Small Cell Lung Cancer|erlotinib + cabozantinib tablet

AK112

EGFR wild-type|Non Small Cell Lung Cancer|AK112

ABBV-647

EGFR wild-type|Non Small Cell Lung Cancer|ABBV-647

pucotenlimab

EGFR wild-type|Lung Non-Squamous Non-Small Cell Cancer|pucotenlimab

atezolizumab + AFM24

EGFR wild-type|Non Small Cell Lung Cancer|atezolizumab + AFM24

anlotinib + cadonilimab

EGFR wild-type|Non Small Cell Lung Cancer|anlotinib + cadonilimab

osimertinib

EGFR wild-type|Tongue Carcinoma|osimertinib

gefitinib

EGFR wild-type|Non Small Cell Lung Cancer|gefitinib

REC-4881

EGFR wild-type|Lung Adenocarcinoma|REC-4881

PD1 inhibitor

EGFR wild-type|Non Small Cell Lung Cancer|PD1 inhibitor

AZD8330

EGFR wild-type|Lung Adenocarcinoma|AZD8330

PF-04691502

EGFR wild-type|Lung Adenocarcinoma|PF-04691502

GSK2126458

EGFR wild-type|Lung Adenocarcinoma|GSK2126458

RTB101

EGFR wild-type|Non Small Cell Lung Cancer|RTB101